Department of Biotechnology | Indian Institute Of Technology Madras , Chennai
team

Suresh Kumar Rayala

Professor

Ph.D., Cancer Institute Madras

M.S., SV University Tirupati

Block 1, BT 306

044 2257 4137

rayala[at]iitm[.]ac[.]in

Lab: Block 1, BT 317

044-2257-5114

Lab Website
Scopus

  • Cancer Biology - Small molecules/peptides targeting novel oncogenes, mechanism of action of new drugs - CRISPR/Cas9 screens, Mechanisms of therapy resistance, and developing pre-clinical models of tumor progression including xenografts (PDEx & PDE Models), Monoclonal antibodies

  1. Kumar AS, Jagadeeshan S, Subramanian A, Chidambaram S, Surabhi R, Singhal M, Pitani R, Davvuru P, Ganesh V and Rayala SK. (2016). "Molecular mechanism of modulation of nuclear receptor coregulator MTA1 - a key molecule involved in Parkinson's disease by Granulocyte Colony Stimulating Factor", J Biol Chem , 291, pp. 12310-321.
  2. Kumar A, Singhal M, Chopra C, Srinivasan S, Surabhi RP, Kanumuri R, Tentu S, Jagadeesan S, Sundaram S, Ramanathan K, Pitani R, Muthuswamy B, Abhijit S, Nair AS, Venkatraman G and Rayala SK (2016). "Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.", Oncogene, 35, pp. 4857-65.
  3. Kumar AS, Jagadeeshan S, Pitani RS, Ramshankar V, Venkitasamy K, Ganesh V and Rayala SK. (2017). "Snail-Modulated MicroRNA 493 Forms a Negative Feedback Loop with the Insulin-Like Growth Factor 1 Receptor Pathway and Blocks Tumorigenesis", Mol Cell Biol , 37, pp. e510-16.
  4. Anuj, Lakshmi A, Surabhi RP, Kanakarajan A, Sundaram S, Pitani RS, Kremersothen J, Ganesh V and Rayala SK (2017). "KIBRA attains oncogenic activity by repressing RASSF1A. ", Br J.Cancer, 117, pp. 553-562.
  5. Beesetti S, Jayadev M, Surabhi R, Kathy T, Pitani RS, Joseph LD, Ganesh V and Rayala SK. (2017). "Transcriptional regulation of ataxia–telangiectasia and Rad3 related protein (ATR) by activated Pak1 protects keratinocytes in UV-B induced premalignant skin lesions. ", Oncogene, 36, pp. 6154-6163.
  6. Kanumuri R, Kumar A, Biswal J, Vignesh R, Pandian J, Venu A, Vaishnavi B, Leena DJ, Jeyaraman J, Ganesan G, Aradhyam GK, Venkatraman G, and Rayala SK. (2021). "Small peptide inhibitor from the sequence of RUNX3 disrupts PAK1-RUNX3 interaction and abrogates its phosphorylation dependent oncogenic function.", Oncogene, 34, pp. 5327-5341.
  7. Vuttaradi VK, Ezhil I, Ramani D, Kanumuri R, Raghavan R, Vaishnavi B, Roshini S, Archana K, Leena DJ, Pitani RS, Sandhya S, Sjolander A, Ganesh V and Rayala SK (2022). "Inflammation induced PELP1 promotes tumorigenesis by activating GM-CSF 2 paracrine secretion in the tumor microenvironment", J Biol Chem, 298, pp. 101406.
  8. Inemai Ezhil, Abirami Seetharaman, Rahul S Kanumuri, Barathidasan R, Ranga Rao G, Ganesh Venkatraman and Suresh Kumar Rayala* (2025). "Novel combination therapy targeting oncogenic signaling kinase P21 activated Kinase-1 and chemotherapeutic drugs against triple negative breast cancer", Molecular Cancer Theraputics, In Press.